| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/17/2006 | EP1656128A1 Treatment for acne vulgaris and method of use |
| 05/17/2006 | EP1656126A1 Preparing method for controlled released type tablet tamsulosin hcl and the tablet thereof |
| 05/17/2006 | EP1656125A2 Topical composition comprising terbinafine and hydrocortisone |
| 05/17/2006 | EP1656124A1 Methods and compositions for the treatment of cancer |
| 05/17/2006 | EP1656123A2 Anti-candida agents for the treatment of prion diseases |
| 05/17/2006 | EP1656122A1 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease |
| 05/17/2006 | EP1656120A1 Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases |
| 05/17/2006 | EP1656118A2 Novel formulation of ropinirole |
| 05/17/2006 | EP1656112A1 Buccal formulations of galanthamine and uses thereof |
| 05/17/2006 | EP1656102A2 Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof |
| 05/17/2006 | EP1656100A1 Topical skin preparations for treatment of skin aging comprising a testosterone ester |
| 05/17/2006 | EP1656096A2 Methods of reducing risk of infection from pathogens |
| 05/17/2006 | EP1656095A2 N,n-dihalogenated amino acids and derivatives |
| 05/17/2006 | EP1656094A2 Methods of improving the safety of zonisamide therapy |
| 05/17/2006 | EP1656093A2 Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| 05/17/2006 | EP1656088A2 Methods of reducing risk of infection from pathogens |
| 05/17/2006 | EP1656022A2 Methods of reducing risk of infection from pathogens |
| 05/17/2006 | EP1558252A4 Substituted furo 2,3-b| pyridine derivatives |
| 05/17/2006 | EP1551821B1 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia |
| 05/17/2006 | EP1543003B1 Imidazo¬1,2-a|pyridines |
| 05/17/2006 | EP1507519B1 Medicament with delayed release of the active substance, containing 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol |
| 05/17/2006 | EP1450782B9 Use of a combination composition comprising propionyl l-carnitine and further drugs for the treatment of erectile dysfunction |
| 05/17/2006 | EP1432712B1 Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
| 05/17/2006 | EP1429811A4 Theurapeutic tropane compounds |
| 05/17/2006 | EP1423391B1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
| 05/17/2006 | EP1377552B1 Metal complexes and therapeutic uses thereof |
| 05/17/2006 | EP1372661B1 Glycol derivatves of xanthines for treating irritable bowel syndrome |
| 05/17/2006 | EP1372611B1 Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer |
| 05/17/2006 | EP1368002B1 Method for producing a floating tablet containing alfuzosine |
| 05/17/2006 | EP1363652B1 Extract of green coffee beans, pharmaceutical composition containing this extract, use for the treatment of depression and alcoholism as well as its process of preparation |
| 05/17/2006 | EP1362047B1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 05/17/2006 | EP1351919A4 Retinol derivatives and process for preparing same |
| 05/17/2006 | EP1349864B1 Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases |
| 05/17/2006 | EP1345929B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345927B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345926B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345925B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1317452B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1317447B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1307202B1 Method for the treatment of overactive bladder |
| 05/17/2006 | EP1280555B1 Pharmaceutical composition comprising furosemide and conivaptan for the treatment of congestive heart failure |
| 05/17/2006 | EP1276463A4 Hemostatic agent, method and carrier for applying a blood clotting agent |
| 05/17/2006 | EP1274711B1 New aza-indolyl derivatives |
| 05/17/2006 | EP1272220B1 Formulation for the prevention of cardiovascular disease |
| 05/17/2006 | EP1265616B1 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate |
| 05/17/2006 | EP1263438B1 Neutral antagonists and use thereof in treating drug abuse |
| 05/17/2006 | EP1246810B1 Piperidinyloxy and pyrrolidinyloxyphenyl oxazolidinones as antibacterials |
| 05/17/2006 | EP1231983B1 Combination of dhea and calcitonin for the treatment of subnormal bone mineral density |
| 05/17/2006 | EP1229894B1 Cosmetic compositions containing chick pea extract and retinoids |
| 05/17/2006 | EP1214598B1 Screening for inhibitors of "paired helical filaments" |
| 05/17/2006 | EP1214409B1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 05/17/2006 | EP1204652B1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 05/17/2006 | EP1200321B1 Valve with a valve stem wiper |
| 05/17/2006 | EP1197221B1 G-csf preparations stabilized over long time |
| 05/17/2006 | EP1156775B1 Reduction of hair growth |
| 05/17/2006 | EP1140881B1 Antithrombotic amides |
| 05/17/2006 | EP1115387B1 Anti-microbial-adhesion fraction derived from vaccinium |
| 05/17/2006 | EP1115372B1 Fast dissolving orally consumable films |
| 05/17/2006 | EP1114035B1 Quinazoline derivatives and pharmaceutical applications thereof |
| 05/17/2006 | EP1113818B1 METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| 05/17/2006 | EP1109787B1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 05/17/2006 | EP1094849B1 Methods for increasing vascularization and promoting wound healing |
| 05/17/2006 | EP1048727B1 Gene encoding novel transmembrane protein |
| 05/17/2006 | EP1007101B1 Improvements in or relating to diagnostic/therapeutic agents |
| 05/17/2006 | EP0975668B1 MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA |
| 05/17/2006 | EP0938900B1 Preventives/remedies for stomatitis |
| 05/17/2006 | EP0937077B1 Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
| 05/17/2006 | EP0923941B1 Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| 05/17/2006 | EP0894136B1 Method of treating muscular disorders |
| 05/17/2006 | CN1774635A Anti-epileptogenic agents |
| 05/17/2006 | CN1774460A Biodegradable polyurethane/urea compositions |
| 05/17/2006 | CN1774450A Cross-linked polysaccharide composition |
| 05/17/2006 | CN1774446A Identification of N-alkylglycine trimers for induction of apoptosis |
| 05/17/2006 | CN1774444A Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders |
| 05/17/2006 | CN1774443A Phosphates of secondary alcohols |
| 05/17/2006 | CN1774442A Phosphate derivatives |
| 05/17/2006 | CN1774440A Benzoxepino-11-piperidylidene compounds and process for production thereof |
| 05/17/2006 | CN1774438A Method for the production of riboflavin of modification B/C in granular form |
| 05/17/2006 | CN1774437A 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands |
| 05/17/2006 | CN1774435A Five-membered heterocyclic derivative |
| 05/17/2006 | CN1774434A Stable ammonium salts of alpha-liponic acid, the production there of and the use of the same |
| 05/17/2006 | CN1774433A Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
| 05/17/2006 | CN1774429A Medicinal composition |
| 05/17/2006 | CN1774428A M-stage kinesin inhibitor |
| 05/17/2006 | CN1774425A Quinazoline compounds |
| 05/17/2006 | CN1774422A 2,3'-bipyridines derivatives as selective cox-2 inhibitors |
| 05/17/2006 | CN1774420A Process for the preparation of N-substituted 2-cyanopyrrolidines |
| 05/17/2006 | CN1774417A A new process for the preparation of 17-phenyl-18, 19, 20-trinor-PGF2A and its derivatives |
| 05/17/2006 | CN1774415A Carbamates useful as fragances |
| 05/17/2006 | CN1774267A Amyloid-binding, metal-chelating agents |
| 05/17/2006 | CN1774265A Drug for nerve regeneration |
| 05/17/2006 | CN1774261A Methods and compositions for the treatment of diseases of the eye |
| 05/17/2006 | CN1774257A Method for preparing a centella asiatica extracts rich in madecassoside and in terminoloside |
| 05/17/2006 | CN1774254A Phosphate derivatives of pharmaceutical products |
| 05/17/2006 | CN1774253A Treatment of refractory tumors using epothilone derivatives |
| 05/17/2006 | CN1774252A Phospholipid derivatives of valproic acid and mixtures thereof |
| 05/17/2006 | CN1774251A Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
| 05/17/2006 | CN1774250A (6-(phenoxy)-pyrido[3,4-d) pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis |
| 05/17/2006 | CN1774249A Use of irinotecan for treatment of resistant breast cancer |
| 05/17/2006 | CN1774248A 联合治疗 Combination therapy |